NCT05070247 2026-01-22A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTakedaPhase 1/2 Terminated61 enrolled 29 charts
NCT02414269 2025-10-08Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinMemorial Sloan Kettering Cancer CenterPhase 1/2 Active not recruiting113 enrolled
NCT05215574 2024-10-10Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting130 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled
NCT05311618 2024-04-01Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting71 enrolled